RhumbLine Advisers
HRTX icon

RhumbLine Advisers’s Heron Therapeutics HRTX Stock Holding History

RhumbLine Advisers’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.5K Buy
195,537
+10,988
+6% +$8.81K ﹤0.01% 3588
2026
Q1 		$148K Sell
184,549
-18,770
-9% -$21.8K ﹤0.01% 3251
2025
Q4 		$264K Sell
203,319
-21,334
-9% -$26.3K ﹤0.01% 3040
2025
Q3 		$283K Buy
224,653
+2,215
+1% +$3.51K ﹤0.01% 3033
2025
Q2 		$460K Buy
222,438
+50,344
+29% +$103K ﹤0.01% 2735
2025
Q1 		$379K Sell
172,094
-5,587
-3% -$10.8K ﹤0.01% 2756
2024
Q4 		$272K Buy
177,681
+1,895
+1% +$3.07K ﹤0.01% 3051
2024
Q3 		$350K Sell
175,786
-8,686
-5% -$20.7K ﹤0.01% 2941
2024
Q2 		$646K Buy
184,472
+44,230
+32% +$136K ﹤0.01% 2485
2024
Q1 		$388K Buy
140,242
+4,445
+3% +$11.2K ﹤0.01% 2813
2023
Q4 		$231K Buy
135,797
+595
+0.4% +$655 ﹤0.01% 3115
2023
Q3 		$139K Sell
135,202
-2,216
-2% -$3.15K ﹤0.01% 3345
2023
Q2 		$159K Buy
137,418
+973
+0.7% +$1.74K ﹤0.01% 3354
2023
Q1 		$206K Buy
136,445
+3,558
+3% +$8.91K ﹤0.01% 2732
2022
Q4 		$332K Buy
132,887
+3,628
+3% +$11.7K ﹤0.01% 2639
2022
Q3 		$545K Buy
129,259
+8,472
+7% +$33.2K ﹤0.01% 2459
2022
Q2 		$337K Buy
120,787
+19,503
+19% +$78.3K ﹤0.01% 2701
2022
Q1 		$579K Sell
101,284
-1,814
-2% -$13.3K ﹤0.01% 2357
2021
Q4 		$941K Sell
103,098
-1,941
-2% -$19.8K ﹤0.01% 2239
2021
Q3 		$1.12M Buy
105,039
+4,210
+4% +$51.3K ﹤0.01% 2171
2021
Q2 		$1.56M Sell
100,829
-4,047
-4% -$64.4K ﹤0.01% 2061
2021
Q1 		$1.7M Sell
104,876
-10,162
-9% -$181K ﹤0.01% 1982
2020
Q4 		$2.44M Buy
115,038
+176
+0.2% +$3.06K ﹤0.01% 1756
2020
Q3 		$1.7M Sell
114,862
-19,964
-15% -$311K ﹤0.01% 1765
2020
Q2 		$1.98M Buy
134,826
+17,110
+15% +$281K ﹤0.01% 1732
2020
Q1 		$1.38M Buy
117,716
+4,489
+4% +$84.4K ﹤0.01% 1742
2019
Q4 		$2.66M Buy
113,227
+12,425
+12% +$275K ﹤0.01% 1641
2019
Q3 		$1.86M Buy
100,802
+1,124
+1% +$20.7K ﹤0.01% 1780
2019
Q2 		$1.85M Buy
99,678
+11,093
+13% +$222K ﹤0.01% 1787
2019
Q1 		$2.17M Sell
88,585
-956
-1% -$25K ﹤0.01% 1659
2018
Q4 		$2.32M Buy
89,541
+30,712
+52% +$844K 0.01% 1548
2018
Q3 		$1.86M Sell
58,829
-572
-1% -$21.3K ﹤0.01% 1701
2018
Q2 		$2.31M Buy
59,401
+10,173
+21% +$324K ﹤0.01% 1598
2018
Q1 		$1.36M Buy
49,228
+6,322
+15% +$143K ﹤0.01% 1806
2017
Q4 		$777K Sell
42,906
-8,214
-16% -$134K ﹤0.01% 2062
2017
Q3 		$826K Buy
51,120
+490
+1% +$7.69K ﹤0.01% 2068
2017
Q2 		$701K Buy
50,630
+6,249
+14% +$90.5K ﹤0.01% 2145
2017
Q1 		$666K Buy
44,381
+9,778
+28% +$135K ﹤0.01% 2133
2016
Q4 		$453K Sell
34,603
-863
-2% -$13.5K ﹤0.01% 2280
2016
Q3 		$611K Buy
35,466
+265
+0.8% +$4.92K ﹤0.01% 2084
2016
Q2 		$635K Buy
35,201
+6,067
+21% +$118K ﹤0.01% 2044
2016
Q1 		$553K Buy
29,134
+80
+0.3% +$1.58K ﹤0.01% 2159
2015
Q4 		$776K Buy
29,054
+2,735
+10% +$73.1K ﹤0.01% 1968
2015
Q3 		$642K Buy
26,319
+4,734
+22% +$158K ﹤0.01% 2063
2015
Q2 		$673K Buy
21,585
+235
+1% +$4.42K ﹤0.01% 2136
2015
Q1 		$311K Buy
21,350
+4,900
+30% +$55.2K ﹤0.01% 2589
2014
Q4 		$165K Buy
16,450
+575
+4% +$4.69K ﹤0.01% 2867
2014
Q3 		$132K Buy
15,875
+1,925
+14% +$17.9K ﹤0.01% 2885
2014
Q2 		$172K Buy
+13,950
New +$167K ﹤0.01% 2887

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

RhumbLine Advisers's HRTX Position: Q2 2026 in Review

RhumbLine Advisers increased its Heron Therapeutics (HRTX) stake by 6% in Q2 2026, buying an estimated $8.81K and bringing the position to 195,537 shares worth $83.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3588.

RhumbLine Advisers first reported a position in HRTX in Q2 2014 and has held it in 49 quarters since. The position peaked at $2.66M in Q4 2019. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • RhumbLine Advisers held 195,537 shares of Heron Therapeutics worth $83.5K as of Q2 2026.
  • RhumbLine Advisers bought 10,988 Heron Therapeutics shares in Q2 2026, an estimated $8.81K.
  • Heron Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3588 holding.
  • RhumbLine Advisers first reported a position in Heron Therapeutics in Q2 2014 and has held it in 49 quarters since.
  • RhumbLine Advisers's Heron Therapeutics position peaked at $2.66M in Q4 2019.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.